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Highlights  
 
 
 Allogeneic transplantation is a valid approach for advanced Hodgkin Lymphoma 
 Pre-transplant comorbidity have a great impact on transplant outcomes  
 Pre-transplant functional imaging analysis predicts post-transplant relapse-rate 
 Long lasting Hodgkin remissions have been observed in post-transplant relapses   
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SUMMARY 
 
 
 
Background. Disease relapse remains an unmet medical need for patients with Hodgkin 
lymphoma (HL)  receiving an allogeneic hematopoietic cell transplantation (HCT).  Methods. With 
the aim of identifying patients at high risk for post-transplant relapse, we retrospectively reviewed 
41 HL patients who had received haploidentical (haplo) non myeloablative (NMA) HCT with high 
dose post-transplant cyclophosphamide (PT-CY) for graft-versus-host (GvHD) prophylaxis. Primary 
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refractory disease, relapse within 6 months from autologous stem cell transplantation (ASCT), age, 
pre-transplant chemotherapy, hematopoietic cell transplantation comorbidity index (HCT-CI), sex 
mismatch, tumor burden and pre-transplant positron-emission tomography (FDG-PET) status, 
assessed by Deauville score, were analyzed as variables influencing outcomes.  
Results.  All but one patient engrafted: median time to neutrophil and platelet recovery were15 
(range 13–23) and 19 (12–28) days, respectively. Cumulative incidence of severe (grade III-IV) 
acute GvHD and 3-year moderate-severe chronic GvHD was 2.4% and 11.8%, respectively. The 3-
year overall (OS), progression free (PFS) and graft relapse free survival (GRFS) were 75.6%, 
43.9%, and 39%, respectively. On multivariate analysis, 3-year OS was significantly worse in 
patients with  HCT-CI ≥ 3 (HR  5.0 95% CI 1.1-21.8 p =0.03). Three-year relapse rate , 3-year PFS 
and 3-year GRFS were significantly worse in patients with HCT-CI ≥ 3 (HR=3.5 95% CI 1.3-9.3 
p=0.01, HR=3.3 95% CI 1.2-9.0 p=0.02 and HR=4.2 95% CI 1.7-9.9 p=0.001, respectively) and in 
patients with a Deauville score ≥ 4 on pre-transplant FDG-PET (HR=4.4 95% CI 1.6-12.4 p=0.005,  
HR=3.8 95% CI 1.5-9.7 p=0.005 and 3.2 95% CI 1.3-7.9 p=0.01, respectively). On univariate 
analysis, 3-year NRM was significantly worse only in patients with a HCT-CI ≥ 3 (HR=17.6 95% CI 
1.4-221.0). Conclusions. Among relapsed/refractory HL patients undergoing haplo NMA HCT with 
PT-Cy, pre-transplant FDG-PET with a Deauville score ≥ 4 and HCT-CI ≥ 3 identified patients at 
high risk of relapse. Moreover, a HCT-CI ≥ 3 was associated with higher NRM and  lower OS.  
 
 
 
BACKGROUND 
 
Althought the majority of patients with Hodgkin lymphoma (HL) are cured by frontline 
combination chemotherapy, around 10-20% will require further therapy for relapse or refractory 
disease [1].  Salvage chemotherapy followed by high-dose chemotherapy with autologous stem 
cells transplantation (ASCT) is the gold standard treatment producing long-term remissions in 
approximately 40–50% of relapsed patients [2]. However, relapse after ASCT is challenging, with a 
reported median survival after ASCT failure ranging between 7.3 and 25 months [3].  
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Both American and European Society for Blood and Marrow Transplantation currently 
recommend allogeneic hematopoieic transplantation (HCT) as the prefered strategy in eligible HL 
patients with chemosensitive relapse after ASCT and an available compatible donor [4, 5], 
whereas, for patients without either HLA identical donors or matched unrelated donor (MUD),  
growing evidence indicates the efficacy and feasibility of HLA haploidentical transplantation with 
post-transplant cyclophosphamide (PT-CY) [6 - 8].  
However, relapse remains a significant cause of HCT failure [1, 6 – 8]. In this setting, the 
early identification of patients at high risk of relapse, it is the first step to conceive risk-adapted 
strategies aiming to reduce disease recurrence and increase survival. Here, we report the clinical 
outcome and predictive factors for relapse of 41 consecutive relapsed/refractory HL patients 
submitted to NMA haploidentical HCT with PT-CY at our Center.  
 
METHODS 
 
Forty-four consecutive patients with HL received a NMA allograft from HLA-haploidentical 
related donors between September 2009 and June 2015 at our institution. Three patients with no 
positron-emission tomography (FDG-PET) status at time of haplo HCT were excluded from data 
analysis. Overall, outcomes of 41 HL patients receiving a haplo HCT were analyzed. All patients 
were treated on institutional protocol that was approved by the institutional review board of the 
study site. No exclusion criteria were used for disease status or chemosensivity. Primary refractory 
disease, relapse within 6 months from ASCT [1], age, number of pre-transplant chemotherapy 
lines, HCT-CI [38], sex mismatch, tumor burden (defined as tumor stage at diagnosis; I-IIA vs IIB-
IV)  and pre-transplant positron-emission tomography (FDG-PET) status, assessed by Deauville 
score [9 - 12], were analyzed as variables influencing outcomes. In surviving patients follow-up 
data were censored at time of follow-up analysis, that is on October 4th 2016 and at the diagnosis 
of engraft failure in patients who failed the HCT.  All patients signed consent forms approved by the 
institutional review board. 
 
Conditioning regimen GVHD prophylaxis 
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All patients received a non-myeloablative regimen consisting of cyclophosphamide (Cy) 
14.5 mg/kg on days - 6 and - 5, fludarabine 30 mg/sqm/day from day  - 6 to day  -2 and low dose 
TBI (2 Gy) on day – 1 [7]. GVHD prophylaxis consisted of post- transplant high-dose of Cy (50 
mg/kg) on days  +3 and +4 ; cyclosporine 1.5mg/kg/day (and then adjusted, accordingly to a blood 
level target between 200 and 400 microg/L) started at day + 5 as continuous infusion, switched as 
twice /day  oral administration at patient discharge and then tapered from day + 100 or on opinion 
of treating physician in case of GVHD, disease progression and mixed-chimera; mycophenolate 
mofetil 15 mg/kg  bid from day +5 until day + 30. Peg-filgrastim 6 mg (Neulasta, Amgen, Thousand 
Oaks, CA) single dose was administered by subcutaneous injection on day +6. 
 
Stem cell source 
 
Unmanipulated bone marrow was the stem cell source in all the patients on day 0. Donors 
underwent BM harvest under general anesthesia, and the ideal target of mononuclear cells was 4 x 
108/kg. [7] 
 
Donor  
 
Family donors, 24 males and 20 females, were all genotypically HLA haploidentical, typed 
on A, B, C and DRB1. Donor/recipient sex was matched in the 50% of cases [37]. 
 
Supportive care 
 
Antimicrobial/fungal prophylaxis and treatment were administered as previously described 
[7] as well as CMV, EBV, HHV-6 and frequent viral infection (e.g. influential, respiratory syncytial 
virus) monitoring and treatment. [7] 
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18F-FDG PET/CT acquisition  
 
All the patients underwent preparation and fluorodeoxyglucose-positron emission 
tomography (FDG PET/CT) according to European guidelines [12] and data were acquired using a 
16-slices PET/CT hybrid system (Biograph 16, Siemens Medical Solutions, Knoxville TN, USA).  
 
Images Analysis 
 
Residual metabolic activity before HCT was assessed by FDG-PET. When available for central 
reviewing, pre-transplant FDG-PET scans were evaluated at Nuclear Medicine Unit of our 
institution, in keeping with the consensus recommendations, by means of the Deauville 5-point 
score [13 - 16]; thus sites of residual uptake before allograft were compared  to the uptake in the 
normal mediastinal blood pool and the liver as follows: Score 1, no uptake; Score 2, uptake ≤ 
mediastinum; Score 3, uptake > mediastinum and ≤ liver; Score 4, uptake moderately increased 
above liver at any site; Score 5, markedly increased uptake above liver and/or new sites of 
disease. A Deauville score 4 or greater was considered as FDG-PET positive. When FDG-PET 
images were not available for central reviewing, pre-transplant FDG-PET status was established 
on the bases of original local report (see results section for further details)  
 
FDG-PET status before NMA allograft 
 
All 41 patients were stratified accordingly to pre-transplant FDG-PET results. In 32 (78%) 
out of 41 patients, pre-transplant FDG-PET scans were centrally reviewed; whereas in the 
remaining 9 patients, clinical charts were reviewed to assess pre-transplant status: patients with 
residual metabolic activity and clearly clinical progressive (5/9 patients) disease were accounted 
FDG-PET positive; asymptomatic patients with complete negative FDG-PET (4/9 patients) report 
were considered FDG-PET negative. Nineteen (46%) out of 41 patients underwent HCT with a 
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FDG-PET negative scan (Deauville < 4); 22 of 41 (54%) with FDG-PET positive scan (Deauville ≥ 
4).  
 
Follow-up and post NMA allograft therapy for relapsed/progressive disease 
 
After 2 months from transplantation, FDG-PET evaluation was performed; subsequent 
scans were decided on physician discretion. The development of new FDG-avid lesions in the 
absence of other potential causative pathologies, or ‘significant’ increase in Standardized Uptake 
Value (SUV) of over 25% in previously positive lesions was considered compatible with 
relapse/progression. Relapse was confirmed by histological study if biopsy was feasible; otherwise 
a FDG-PET/CT studies were repeated at 6–8 weeks to confirm progression. 
Patients experiencing relapse were eligible for chemotherapy by treating physician (mainly 
rituximab 375 mg/mq day 1 and bendamustine 90 mg/mq days 1 -2; in selected cases, 
gemcitabine, brentuximab vedotin, nivolumab, involved-field radiotherapy (RT) and donor 
lymphocyte infusion (DLI) were used. Dose of DLI started at 1 x10^3/kg CD3+ cells and was 
increased every 1–2 months by half log, up to 1 x10^7/kg. Patients with mixed-chimeras, as 
assessed by PCR analysis of short tandem-repeat loci, were treated with cyclosporine withdrawal 
or DLI.  
 
Statistical Analysis 
 
Primary refractory HL was defined as progression or no complete remission after front-line 
treatment. Salvage chemotherapy with subsequent ASCT was, overall, considered one line of 
therapy. Radiotherapy was considered as line of therapy if used for localized relapsed disease; it 
was considered as part of the chemotherapy if used as consolidation for bulky mass. Neutrophil 
recovery was considered a neutrophil count ≥ 0.5 x 109/L for more than 2 consecutive days without 
G-CSF support); platelet recovery was considered a platelet count ≥ 20 x 109/L for more than 2 
consecutive days without transfusions. GvHD diagnosis and clinical grading were performed as 
described literature [17; 18]. Non-relapse mortality (NRM) was defined as death without disease 
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recurrence or persistence. When estimating cumulative incidence, relapse was a competing risk for 
non-relapse mortality (and vice versa). GRFS is a novel composite end point recently proposed 
[33; 34] in the evaluation of both standard and novel transplant platform. GRFS events were 
defined as grade 3-4 acute GVHD, chronic GVHD requiring systemic immunosuppressive 
treatment, disease relapse, or death from any cause. Kaplan-Meier estimates were used to 
determine the unadjusted probability of overall survival (OS), progression free survival (PFS) and 
GRFS among patients who underwent FDG-PET with differences between the curves determined 
using log-rank tests. 
Continuous variables are presented as median (1st-3rd quartiles), whereas categorical 
variables are presented as frequencies. Statistical comparisons across categorical factors, not 
including time-to-event data, were completed with the χ-square test. Continuous factors were 
compared by the U-Mann-Whitney test for nonparametric data. Cox univariate and multivariate 
regression model was performed to identify pre-transplant factors influencing outcomes. Only 
factors significantly associated with outcome in univariate analysis were included in a multivariate 
model following a stepwise procedure. 
Fine and Gray model for competing risks [19; 20] was used to assess the impact of FDG-PET on 
the study outcomes. Sub-distribution hazard ratio (SHR) and relative 95% confidence intervals (CI) 
were shown for Fine and Gray model. Cumulative incidences with competing risk analysis [21] 
were calculated for relapse, non-relapse mortality, acute and chronic GVHD. Graft failure, relapse, 
and death were considered competing events when estimating the cumulative incidence of GVHD. 
Values of P < 0.05 were considered statistically significant. All analyses were performed using SAS 
version 9.3 (SAS Institute, Cary, NC) and R. 
 
RESULTS 
Patient characteristics are reported in Table 1. This study enrolled heavily pre-treated HL 
patients with at least 3 conventional chemotherapy lines before HCT. Most of them (30 out of 41; 
73%) were refractory to front-line chemotherapy. Front-line therapy were ABVD (adriamycin, 
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bleomycin, vinblastine, dacarbazine) regimens in almost all case. Salvage chemotherapy for 
relapsed/refractory disease were IGEV (ifosfamide, gemcitabine, vinorelbine, and prednisolone) 
DHAP/DHAOX (dexamethasone, cisplatin/oxaliplatin, and cytarabine) or 
BEACOPP/BEACOPPescaleted (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, 
prednisone) regimens in most of case. Twenty-six of 41 (63%) patients were exposed to 
radiotherapy, either as consolidation on bulky disease or as regional treatment of relapse. Twenty-
two of 41 (54%) had received brentuximab vedotin and 40 of 41 (97%) had been submitted to 
ASCT.  Five patients underwent to tandem transplantation with haplo transplantation performed 
after a median time of 96 days (range 78-166) from ASCT. No patient was exposed to checkpoint 
inhibitor therapy prior of haplo transplant. 
 
Engraftment  
 
All but 1 patient engrafted; the patients who failed allogeneic transplant  showed autologous 
neutrophil and platelet recovery after re-infusion of cryopreserved autologous stem cells. Median 
times to neutrophil and platelet recovery were respectively 15 days (range 13–23) and 19 (12–28). 
All patients were evaluable for chimerism from day +30 post-transplant  on unfractionated marrow 
cells, as well as on peripheral blood CD3+ selected cells. Four (10%) out of 41 patients were 
mixed chimeras (7–21% recipient). All converted to full donor status (0% recipient) in subsequent 
chimerism follow-up assessment. In 1 out of 4 patients with a mixed chimeras (21% recipient) 
cyclosporine was halved on day 53 from transplant. In the other 3 patients with mixed-chimeras (7-
10% recipient) no interventions were adopted. 
 
GVHD 
 
 The 100-day cumulative incidences of acute GVHD of grade II–IV was 20.7% (95%CI: 
19.9%-21.6%). Severe acute GVHD of grade III-IV was diagnosed in only one patient (the event 
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occurred after 27 days). The 100-day cumulative incidences of acute GVHD of grade III–IV was 
2.4% (95%CI: 2.3%-2.6%).  
Overall, 5 patients developed chronic GVHD of grade moderate-severe, with a 3-year cumulative 
incidence of 11.8% (95%CI: 11.1%-12.5%). Sites of cGVHD were skin  (2 patients), lung (2 
patients) and both skin and lung in the other patient. All five patients were treated with steroids 1 
mg/kg; two patients received also mycophenolate mofetil; one cyclosporine; and one 
extracorporeal photopheresis. None of the five patients were exposed to checkpoint inhibitor prior 
of GVHD 
 
NRM, PFS, GRFS and OS 
 
Median follow-up for surviving patients was 3.25 years (range 1.29 – 7.06); 3-year 
cumulative incidence of NRM was 7.5% (95%CI: 7.0%-8.1%) (Figure 1c). Causes of NRM were 
cGVHD, myocarditis and pneumonia and occurred respectively at 8, 16 and 51 months from HCT. 
Overall, relapse/progression was diagnosed in 20 patients, resulting in a 3-year cumulative 
incidence of relapse of 55.4% (95%CI: 53.8%-57.0%) (Figure 1d). Median time to relapse was 9 
months (5 - 14). Seven relapses were histologically documented whereas in 13 patients, relapses 
were diagnosed with imaging analysis as described in M and M. Seven  patients (35%) died of 
progressive disease; 7 (35%) are currently off-therapy in clinical and radiological remission and 6 
(30%) with ongoing therapy. The most commonly used therapy for post HCT relapse was a 
combination of immune-chemotherapy and DLI. Thirteen patients received R-Bendamustine and 
DLI; among them 5 patients received also brentuximab vedotin, 2 patients radiotherapy, and 1 
patient nivolumab. The remaining 6 patients were treated with chemotherapy and/or radiotherapy 
without the use of DLI.  
Eighteen out of 41  patients (43%) are in continuous complete remission after HCT.   
Overall, Kaplan-Meier estimates for 3-year OS, PFS and GRFS were 75.6%, 43.9% and 
39%, respectively (Figure 2). Outcomes analysis accordingly to pre-transplant variables is shown 
on table n. 3 and 4; and on figure 3 and 4. 
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Univariate analysis 
 On univariate analysis, 3-year NRM was significantly worse only in patients with a HCT-CI 
of 3 or greater (HR=17.6 95% CI 1.4-221.0). Pre-transplant FDG-PET did not impact on acute 
GVHD (HR=0.9; 95%CI: 0.5-1.8; p=0.86), chronic GVHD (HR=1.3; 95%CI: 0.2-7.0; p=0.79) and on 
3-year overall survival (HR=2.0; 95%CI: 0.5-7.8; p=0.31).   
 
Multivariate Cox analysis 
 In a multivariate Cox analysis, the 3-year OS was significantly worse in patients with HCT-
CI of 3 or greater (HR  5.0 95% CI 1.1-21.8 p =0.03). Three-year relapse rate , 3-year PFS and 3-
year GRFS were significantly worse in patients with HCT-CI of 3 or greater (HR=3.5 95% CI 1.3-
9.3 p=0.01, HR=3.3 95% CI 1.2-9.0 p=0.02 and HR=4.2 95% CI 1.7-9.9 p=0.001, respectively) and 
in patients with a Deauville score of 4 or greater on pre-transplant FDG-PET (HR=4.4 95% CI 1.6-
12.4 p=0.005,  HR=3.8 95% CI 1.5-9.7 p=0.005 and 3.2 95% CI 1.3-7.9 p=0.01, respectively). Of 
note, all 5 patients treated according to tandem strategy achieved CR after ASCT and underwent 
to HCT with a negative FDG-PET scan (Deaville score ≤ 3). However, 2/5 patients relapsed at 5 
and 12 months after transplant. 
 
Value of the first post HCT FDG-PET scan 
 
Thirty-eight post-transplant FDG-PET scans were available for central reviewing. The 
median time of the first post-transplant FDG-PET assessment was 66 days (51-76). The FDG-PET 
scan was negative in 35 out of 38 (92%) and positive in 3 out 38 (8%) patients. In these patients, 
pre-transplant FDG-PET was positive in two subjects who subsequently died for progressive 
disease. The third patient, who had a negative pre-transplant FDG-PET, was treated for disease 
relapse, and is still alive after 364 days after transplant.  
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Among 35 patients with a negative post-transplant FDG-PET, 14 (40%) relapsed. 
Regarding the predictive value of post-transplant imaging, the calculated negative predictive value 
of a negative FDG-PET scan was just 60% (95% CI 54.6% - 65.1%).  
 
DISCUSSION 
 
We confirm, here, the feasibility and the efficacy of NMA haplo transplant in heavily pre-
treated HL patients. The transplant procedure was well tolerated with high rate of engraftment, low 
incidence of GVHD and NRM as shown in with previous papers [6 – 8]. Indeed, the graft-versus-
lymphoma effect may overcome the chemo-refractoriness of the disease allowing to reach a 3 
years OS and PFS of 75.6% and 43.9%, respectively, supporting the role of allogeneic 
transplantation in advanced disease [6 - 8; 22]. In our single center analysis, having a HCT-CI of 3 
or greater was the only factor influencing OS. In our study, most of the comorbidity influencing the 
HCT-CI value were results of toxicity of previous treatment, as showed on univariate analysis 
where pre-transplant chemotherapy burden was the only other significant factor associated with a 
worse OS. This result, although to be confirmed in other studies, should raise question on the 
timing of HCT procedure and advocate a more comprehensive and collegial approach between 
chemotherapy wards and transplant center. Moreover, having a HCT-CI ≥ 3 and a Deauville score 
≥ 4 on pre-transplant FDG-PET were associated with higher relapse rate, lower PFS and GRFS. 
Whereas in the autograft setting the role of pre-transplant FDG-PET is well established [23 -  27], 
few and discordant papers have been published on FDG-PET assessment before allograft [9 – 12]. 
Moreover, previous studies have addressed this issue either on heterogeneous patient’s 
population [9] or on hematological malignancies other than Hodgkin lymphoma [10 -12]. Recently, 
Reyal et al., published the results of a large multicenter and retrospective study on HL patients 
undergoing a myeloablative, T Cell-Depleted Allogeneic Transplantation [28]. In that paper, the role 
of pre-transplant FDG-PET was questioned. However, the platform used to perform HCT was 
significantly different (e.g. T-cell depletion, more intense conditioning regimen). On the other hand, 
if our results will be confirmed in other reports, FDG-PET status before an NMA allograft might be 
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one of criteria to consider tailoring post-transplant immunemodulation, such as early cyclosporine 
withdrawal or prophylactic post-transplant therapy with DLI and checkpoint inhibitors. Moreover, 
our study highlighted that patients relapsing after a NMA allograft, might still achieve long lasting 
remission with immune-chemotherapy,  IF-RT, immune checkpoint inhibitor and DLI [35]. We also 
found that the first post-transplant FDG-PET had a low negative predictive value for disease 
relapse. The standard practice of performing post-transplant FDG-PET follow-up, especially for 
those patients in complete metabolic remission before transplantation, might be challenged.  
 The main limit of our study is the retrospective nature of the analysis and the various 
chemotherapy strategies used before transplantation. The great variability of salvage therapy used 
and the reference, on a national basis, of patients from other centers than our, not allowed us to 
properly assess the quality of response to salvage chemotherapy. Given the significant prognostic 
value of “chemosensitive” and “chemorefractory” cathegories [36] in HL population, we hope that 
future clinical trials will be able to correlate quality of response after salvage chemotherapy with 
pre-transplant FDG-PET Deauville score,  to design early strategies of post-transplant 
immunomodulation.  
In conclusion, we suggest the potential role of PET and HCT-CI before NMA haplo 
transplant to identify a patient population at high risk for early relapse and/or transplant failure . 
This hypothesis should be investigated in a prospective, multicenter study integrating novel 
strategies of relapse prevention. 
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Figure 1: Cumulative incidence of outcomes in all 41 patients. A) acute GVHD. B) chronic GVHD. 
C) non-relapse mortality (NRM). D) relapse rate  
A) acute GVHD 
 
 
B) chronic GVHD 
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C) NRM 
 
 
D) relapse rate 
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Figure 2: Kaplan-Meier estimates of overall survival (OS), progression free survival (PFS) and 
graft relapse free survival (GRFS) 
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Figure 3: Cumulative incidence of  disease relapse accordingly to pre-transplant FDG-PET 
status (positive if Deauville score ≥ 4) 
 
 
 
 
 
 
 
 
 
 
 
 
  
p = 0.005 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
20 
 
 
Figure 4: Kaplan-Meier estimates a) overall survival b) progression free survival c) GRFS 
relapse accordingly to pre-transplant FDG-PET status (positive if Deauville score ≥ 4) 
 
a) overall survival accordingly to pre-transplant PET status 
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b) progression free survival accordingly to pre-transplant PET status 
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c) GRFS relapse accordingly to pre-transplant PET status 
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Table 1. Demographic, treatment and clinic characteristics of the 41 patients who received 
NMA haplo alloSCT. Data are expressed as medians (1st-3rd quartiles) or absolute 
frequencies (percentage). 
  All patients 
N. 41 
Median Age, years 34 (25.7-37.0) 
Gender (Male) 25 (60.9) 
Donor/receiving mismatch 19 (46.0) 
     Mismatch with female donor 12 (29.2) 
Response to the first therapy lines 
 
     Refractory 30 (73.1) 
     Relapsed 11 (27.9) 
ASCT 40 (97.5) 
    As bridge to allograft 5/40 (12.5) 
    As part of Salvage Chemotherapy 35/40 (87.5) 
Median time to ASCT failure (months) 4.5 (0-8.8) 
Brentuximab (SGN35) 22 (53.6) 
Previous radiotherapy 26 (63.4) 
Median number of therapy lines 4 (4-6) 
Time from diagnosis to alloSCT (months) 34.6 (22.8-60.8) 
CMV serostatus  
    pos/pos 22 (53.7) 
    neg/pos 7 (17.1) 
    neg/neg 4 (9.7) 
    pos/neg 8 (19.5) 
TOTAL CELLS*10^8 3.6 (2.6-4.1) 
CD34+*10^6 3.9 (3.2-5.7) 
CD3+*10^6 35.3 (25.1-46.9) 
HCT–CI ≥ 3 8 (19.5) 
Pre-allo FDG-PET positive (Five-point Deauville scale ≥4) 22 (53.7) 
Engraftment 40 (97.5) 
 
ASCT: autologous stem cell transplantation; HCT-CI: Hematopoietic Cell Transplantation Comorbidity 
Index; FDG-PET: Positron emission tomography 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
24 
 
Table 2. Demographic, treatment clinic and characteristics among patients who underwent 
positron emission tomography (FDG-PET). The FDG-PET was considered positive when 
Five-point Deauville scale was ≥ 4. Data are expressed as medians (1st-3rd quartiles) or 
absolute frequencies (percentage). 
 
  
FDG-PET  
Positive 
FDG-PET 
 Negative 
p-value 
N 22 19  
Median Age, years 31.1 (26.1-36.2) 30.5 (25.8-39.5) 0.948 
Gender (Male) 14 (63.6) 11 (36.4) 0.707 
Gender Match 8 (36.4) 13 (68.4) 0.04 
Response to the first therapy lines 
 
 0.138 
     Refractory 14 (63.6) 16 (84.2)  
     Relapse 8 (36.4) 3 (15.8)  
autoSCT 
 
 1.0
§
 
    As bridge to Allo ASCT 1 (4.8) 1 (5.3)  
    As part of Salvage Chemiotherapy 20 (95.2) 18 (94.7)  
Median time to autoSCT failure (months) 5.0 (0-10.2) 0.0 (0.0-8.2) 0.237 
Brentuximab (SGN35) 9 (40.9) 13 (68.4) 0.078 
Previous radiotherapy 15 (68.2) 11 (57.9) 0.495 
Median number of therapy lines 4 (3-5) 4 (4-6) 0.484 
Time from diagnosis to transplant (months) 33.9 (23.4-62.6) 33.1 (21.0-54.4) 0.509 
CELLS*10^8 3.6 (3.0-4.2) 3.3 (2.2-4.1) 0.216 
CD34*10^6 4.2 (3.2-5.7) 3.5 (3.0-5.9) 0.938 
cd3*10^6 35.3 (26.8-49.3) 33.9 (24.5-49.0) 0.650 
§ Fisher ‘s Exact Test; autoSCT: autologous stem cell transplantation; FDG-PET: Positron 
emission tomography 
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Table 3.  Univariate and multivariate Cox analysis  for overall survival, non-relapse 
mortality, relapse rate, progression free survival and graft-relapse free survival accordingly 
to pre-transplant variables 
 
Table 3. Univariate and multivariate Cox analysis  for overall survival, non-relapse mortality, 
relapse rate, progression free survival and graft-relapse free survival accordingly to pre-
transplant variables  
Variable 
3-year OS 
HR  
(95%CI) 
3-year NRM 
HR  
(95%CI) 
3-year Relapse 
Rate 
HR  
(95%CI) 
3-year PFS 
HR  
(95%CI) 
3-year GRFS 
HR  
(95%CI) 
 Univ. Cox Univ. Cox Univ. Cox Univ. Cox Univ. Cox 
Pre-transplant 
FDG -PET  
(Deauville ≥ 
4 vs < 4)   
2.0 
(0.5-
7.8) 
p=0.31 
 
0.6 
(0.1-
7.0) 
p=0.70 
 
3.9 
(1.4-
10.7) 
p=0.01 
4.4  
(1.6-
12.4)  
p=0.005 
2.7 
(1.1-
6.7) 
p=0.03 
3.8  
(1.5-
9.7)  
p=0.005 
3.2 
(1.3-
7.7) 
p=0.01 
3.2  
(1.3-
7.9)  
p=0.01 
Response to 
the first 
therapy lines 
(Refractory 
vs 
responders) 
0.9 
(0.2-
3.5) 
p=0.89 
 
0.8 
(0.1-
9.3) 
p=0.89 
 
1.2 
(0.4-
3.2) 
p=0.75 
 
1.2 
(0.5-
3.1) 
p=0.67 
 
1.5 
(0.6-
3.8) 
p=0.37 
 
Time from 
ASCT to 
relapse   
(≤ 6 months 
vs > 6 
months) 
0.6 
(0.2-
2.2) 
p=0.42 
 
0.4 
(0.04-
4.8) 
p=0.49 
 
1.1 
(0.4-
2.8) 
p=0.84 
 
1.0 
(0.4-
2.4) 
p=0.99 
 
1.2 
(0.5-
2.8) 
p=0.68 
 
Number of 
pre-transplant 
therapy lines 
(continuous) 
1.7 
(1.1-
2.4) 
p=0.01 
1.3  
(0.8-
2.0) 
p=0.23 
2.7 
(0.9-
7.8) 
p=0.07 
 
1.3 
(1.0-
1.8) 
p=0.09 
 
1.4 
(1.0-
1.9) 
p=0.03 
1.3  
(1.0-
1.8) 
p=0.06 
1.2 
(0.9-
1.7) 
p=0.12 
 
Age 
(continuous) 
1.0 
(0.9-
1.1) 
p=0.98 
 
1.0 
(0.9-
1.1) 
p=0.59 
 
1.0 
(1.0-
1.0) 
p=0.85 
 
1.4 
(1.0-
1.9) 
p=0.03 
1.0  
(1.0-
1.1) 
p=0.60 
1.0 
(1.0-
1.0) 
p=0.55 
 
HCT-CI  
(≥ 3 vs < 3) 
7.7 
(2.2-
27.2) 
p=0.002 
5.0  
(1.1-
21.8)  
p=0.03 
17.6 
(1.4-
221.0) 
p=0.03 
 
2.8 
(1.1-
7.3) 
p=0.04 
3.5  
(1.3-
9.3)  
p=0.01 
4.0 
(1.7-
9.7) 
p=0.002 
3.3 
(1.2-
9.0) 
p=0.02 
4.2 
(1.8-
9.8) 
p=0.001 
4.2 
(1.7-
9.9) 
p=0.001 
Donor-
receiving sex 
mismatch 
(F/M vs other 
combination) 
1.3 
(0.3-
6.3) 
p=0.72 
 
4.3 
(0.3-
69.8) 
P=0.31 
 
0.7 
(0.2-
2.4) 
p=0.57 
 
1.0 
(0.3-
3.0) 
p=0.99 
 
0.8 
(0.3-
2.5) 
p=0.77 
 
Tumor 
burden 
(stage IIB-IV 
vs I-IIA)  
 
1.9 
(0.2-
15.1) 
p=0.55 
 
1.1 
(0.1-
16.7) 
p=0.94 
 
17.2 
(0.9-
328.9) 
p=0.99 
 
6.5 
(0.9-
49.4) 
p=0.07 
 
7.8 
(1.0-
59.0) 
p=0.05 
 
OS: Overall Survival; NRM: non-relapse mortality; PFS: Progression free survival; GRFS: Graft relapse free 
survival 
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Table 4. Outcomes accordingly to pre-transplant FDG-PET status (positive if Deauville ≥ 4) 
 
Pre-transplant 
PET status  
(n of pts) 
n of pts 
relapsed 
(%) 
3 year 
Relapse 
Rate 
Grade II-IV 
aGvHD 
3 year 
cGvHD 
3 year 
PFS 3 year OS 
3 year 
GRFS 
Positive  
(22) 
 
15/22 
(68) 72.7% 0.0% 12.3% 27.3% 68.2% 18.2% 
Negative 
(19) 
 
5/19  
(26) 33.9% 5.3% 10.5% 63.2% 84.2% 63.2% 
p-value 
 
0.01 0.86 0.79 0.02 0.31 0.01 
 
FDG-PET: Positron emission tomography 
 
